Transce3nd’s GSK GSK Stock Holding History

Transce3nd’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-28	Closed	-$1.06K	–	564
2025 Q2	$1.06K	Hold	28	–	–	﹤0.01%	971
2025 Q1	$1.07K	Sell	28 -616	-96%	-$22.6K	﹤0.01%	947
2024 Q4	$21.8K	Buy	+644	New	+$23.2K	0.01%	538

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Transce3nd's GSK Position: Q3 2025 in Review

Transce3nd sold out of GSK (GSK) in Q3 2025, closing a stake of 28 shares — an estimated $1.06K sold.

Transce3nd first reported a position in GSK in Q4 2024 and held it in 3 quarters. The position peaked at $21.8K in Q4 2024. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Transce3nd reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 28 GSK shares in Q3 2025, an estimated $1.06K.
Transce3nd first reported a position in GSK in Q4 2024 and held it in 3 quarters.
Transce3nd's GSK position peaked at $21.8K in Q4 2024.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.